

PAX-8 (MD-50 also known as MRQ-50)

Mouse Anti-PAX8 Monoclonal Antibody (Clone MD-50 also known as MRQ-50)

References and presentations¹

- **ready-to-use (manual or LabVision AutoStainer)**
MAD-000550-QD – 3
MAD-000550-QD – 7
MAD-000550-QD – 12
- **concentrated**
MAD-000550-Q - 1:50 recommended dilution

Composition: anti-PAX8 mouse monoclonal antibody obtained from supernatant culture and prediluted in a tris buffered solution pH 7.4 containing 0.375mM sodium azide solution as bacteriostatic and bactericidal.

Intended use^{IVD}: Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

Clone: MD-50 also known as MRQ-50

Ig isotype: mouse IgG

Species reactivity: In vitro diagnostics in humans. Not tested in other species

Description and applications: The PAX 8 protein is a transcription factor and is a member of the PAX family that characteristically contains a type "box" paired domain. PAX 8 is an important factor for the embryological development of the thyroid, the Müllerian system, kidneys, and the upper urinary tract. PAX 8 continues to be expressed in adult thyroid tissue and is detected in normal renal epithelium, in all segments of the renal tubules from the proximal tubule to the renal papilla and parietal epithelium of Bowman's capsule.

An intense PAX8 nuclear signal is present in: thyroid tumors, clear cell renal cell carcinomas (CRCC), sarcomatoid CRCCs, renal oncocytomas, renal chromophobe carcinomas, and renal medullary carcinomas; also serous ovarian carcinomas of high degree, non-serous ovarian epithelial neoplasms, cervical epithelial lesions, endometrial adenocarcinomas, and a subset of thymic carcinomas might also be positive. Weak and focal positivity may occur in very rare cases of urothelial bladder carcinomas, squamous cell carcinomas,



adenocarcinomas of the esophagus, pancreas, cholangiocarcinomas, ovarian tumors, Sertoli-Leydig cells, ovarian sex cord stromal tumors, testicular mixed germ cell tumors, and acinar cell carcinomas. No PAX8 staining was observed in breast carcinomas, adenocarcinomas and small cell carcinomas of the lung, the majority of gastrointestinal tumors (colon, stomach), prostate tumors, liver, adrenal gland carcinomas, and head and neck carcinomas. These results demonstrate that PAX8 is a highly sensitive marker for thyroid, kidney, Mullerian, and thymus tumors.

IHC positive control: Fallopian tube, kidney

Visualization: Nuclear

IHC recommended procedure:

- 4µm thick section should be taken on charged slides; dry overnight at 60°
- Deparaffinise, rehydrate and HIER (heat induced epitope retrieval) – boil tissue in the Pt Module using Vitro S.A EDTA buffer pH8² for 20 min at 95°C. Upon completion rinse with 3-5 changes of distilled or deionised water followed by cooling at RT for 20 min
- Endogenous peroxidase block - Blocking for 10 minutes at room temperature using peroxidase solution (ref. MAD-021540Q-125)
- Primary antibody: incubate for 10 minutes [The antibody dilution (when concentrated) and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be determined by the individual laboratory]
- For detection use Master Polymer Plus Detection System (HRP) (DAB included; ref. MAD-000237QK)
- Counterstaining with haematoxylin and final mounting of the slide

STORAGE AND STABILITY:  Stored at 2-8°C. Do not freeze.  Once the packaging has been opened it can be stored until the expiration date of the reagent indicated on the label. If the reagent has been stored under other conditions to those indicated in this document, the user must first check its correct performance taking into account the product warranty is no longer valid.

¹ These references are for presentation in vials of Low Density Polyethylene (LDPE) dropper. In case the products are used in automated stainers, a special reference is assigned as follows:

- / L: Cylindrical screw-cap vials (QD-3 / L, QD-7 / L, QD-12 / L).

- / N: Polygonal screw-cap vials (QD-3 / N, QD-7 / N, QD-12 / N).

For different presentations (references / volumes) please contact the supplier.

² Ref: MAD-004072R/D



Vitro S.A.

Calle Luís Fuentes Bejarano 60 Ed. Nudo Norte Local 3 41020 Sevilla (Spain)

Tel: +34 954 933 200. vitra@vitro.bio ; www.vitro.bio



Rev.: 2020-09-21

Warnings and precautions:

1. Avoid contact of reagents with eyes and mucous membranes. If reagents come into contact with sensitive areas, wash with copious amounts of water.
2. This product is harmful if swallowed.
3. Consult local or state authorities with regard to recommended method of disposal.
4. Avoid microbial contamination of reagents.

SAFETY RECOMMENDATIONS










This product is intended for laboratory professional use only. The product is NOT intended to be used as a drug or for domestic purposes. The current version of the Safety Data Sheet for this product can be downloaded by searching the reference number at www.vitro.bio or can be requested at regulatory@vitro.bio.

BIBLIOGRAPHY

1. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. *Am J Surg Pathol*; 26(8):1016-1023. 2002.
2. Di Palma T, Nitsch R, Mascia A, Nitsch L, Di Lauro R, Zannini M. The paired Domain-containing factor Pax8 and the homeodomain-containing factor TTF-1 directly interact and synergistically activate transcription. *J. Bio Chem*; 278(5): 3395-3402. 2003.
3. Zhang P, Zuo H, Nakamura Y, Nakamura M, Wakasa T, Kakudo K. Immunohistochemical analysis of thyroid-specific transcription factors in thyroid tumors. *Pathol Int*; 56: 240-245. 2006.
4. Bowen NJ, Logani S, Dickerson EB, Kapa LB, Akhtar M, Benigno BB, McDonald JF. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. *Gynecol oncol*; 104 (2):331-7. 2007.
5. Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (Fox E1) in thyroid epithelial neoplasms. *Mod. Pathol*; 21: 192-200. 2008.
6. Nonaka D, Chiriboga L, Soslow RA. Expression of PAX8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. *Am J Surg Pathol*; 32 (10):1566-71. 2008.
7. Lotan TL, Ye H, Melamed J, Wu XR, Shih leM, Epstein JI. Immunohistochemical panel to identify the primary site of invasive micropapillary carcinoma. *Am J Surg Pathol*. 33(7):1037-1041. 2009.
8. Tong GX, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM, O'Toole KM. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. *Modern Pathology*; 22: 1218-1227. 2009.
9. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS. A comprehensive analysis of PAX8 expression in human epithelial tumors. *Am J Surg Pathol*; 35(6): 816-826. 2011.

LABEL AND BOX SYMBOLS

Explanation of the symbols of the product label and box:

	Expiration date
	Temperature limit
	Manufacturer
	Sufficient content for <n> assays
	Catalog number
	Lot code
	Refer to the instructions of use
	Medical product for <i>in vitro</i> diagnosis.
	Material safety data sheet